Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms-Reference-Cited by-同舟云学术

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

Published:2024-04-17 Issue:6 Volume:38 Page:1427-1431
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Winter Susann^ORCID,Schneider Marie^ORCID,Oelschlaegel Uta^ORCID,Maggioni Giulia,Riva Elena^ORCID,Raddi Marco Gabriele,Bencini Sara,Peruzzi Benedetta,Choy Desmond,Antunes Dos Reis Rita^ORCID,Güse Esther,Lischer Christopher^ORCID,Vera Julio,Timms Jessica A.,Sompairac Nicolas^ORCID,Sockel Katja^ORCID,Poloni Antonella,Tunger Antje,Della Porta Matteo Giovanni^ORCID,Santini Valeria^ORCID,Schmitz Marc,Platzbecker Uwe^ORCID,Kordasti Shahram^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02249-z.pdf

Reference15 articles.

1. Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, et al. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia. 2022;36:2894–902.

2. Lieu YK, Liu Z, Ali AM, Wei X, Penson A, Zhang J, et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc Natl Acad Sci USA. 2022;119:e2111703119.

3. Clough CA, Pangallo J, Sarchi M, Ilagan JO, North K, Bergantinos R, et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood. 2022;139:2038–49.

4. Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, et al. SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Blood. 2017;130:881–90.

5. Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–47.